Replies to post #3802 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

I don't recall any relatively early stage bio's buying back stock much less one that would raise money in the low teens only to buy back in the high teens a few months later.

If MNTA actually implemented Palo Alto’s recommendation, MNTA would probably be sued by shareholders alleging management malfeasance for buying back the same shares at a higher price.

Palo Alto comes across in this incident as clueless, disingenuous, or both.